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Background: Previous publications indicate that Alzheimer's Disease (AD) related cortical atrophy may develop
in asymmetric patterns, with accentuation of the left hemisphere. Since fluorodeoxyglucose positron emission
tomography (FDG PET) measurements of the regional cerebral metabolic rate of glucose (rCMRgl) provide a
sensitive and specific marker of neurodegenerative disease progression, we sought to investigate the longitudinal
pattern of rCMRgl in amyloid-positive persons with mild cognitive impairment (MCI) and dementia, hypothe-
sizing asymmetric declines of cerebral glucose metabolism.
Methods: Using florbetapir PET and cerebrospinal fluid (CSF) measures to define amyloid-β (Aβ) positivity, 40
Aβ negative (Aβ-) cognitively unimpaired controls (CU; 76 ± 5y), 76 Aβ positive (Aβ+) persons with MCI
(76 ± 7y) and 51 Aβ+persons with probable AD dementia (75 ± 7y) from the AD Neuroimaging Initiative
(ADNI) were included in this study with baseline and 2-year follow-up FDG PET scans. The degree of later-
alization of longitudinal rCMRgl declines in subjects with Aβ+MCI and AD in comparison with Aβ- CU were
statistically quantified via bootstrapped lateralization indices [(LI); range− 1 (right) to 1 (left)].
Results: Compared to Aβ- CU, Aβ+MCI patients showed marked left hemispheric lateralization (LI: 0.78). In
contrast, modest right hemispheric lateralization (LI: −0.33) of rCMRgl declines was found in Aβ+persons
with probable AD dementia. Additional comparisons of Aβ+groups (i.e. MCI and probable AD dementia)
consequently indicated right hemispheric lateralization (LI: −0.79) of stronger rCMRgl declines in dementia
stages of AD. For all comparisons, voxel-based analyses confirmed significant (pFWE<0.05) declines of rCMRgl
within AD-typical brain regions. Analyses of cognitive data yielded predominant decline of memory functions in
both MCI and dementia stages of AD.
Conclusions: These data indicate that in early stages, AD may be characterized by a more lateralized pattern of
left hemispheric rCMRgl declines. However, metabolic differences between hemispheres appear to diminish with
further progression of the disease.
1. Introduction
Alzheimer's disease (AD) is the most common cause of cognitive
impairment in older persons. In recent years, AD has been
conceptualized as a progressive sequence of pathophysiological changes
that include the extracellular accumulation of amyloid-β (Aβ), tau-
mediated neuronal dysfunction/death and brain atrophy that corre-
spond roughly to cognitively unimpaired, mild cognitive impairment
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(MCI) and dementia stages (Jack et al. 2011, 2018).
Brain imaging measurements have been used to detect and track Aβ,
tau, and neurodegenerative features of AD in the preclinical (cogni-
tively unimpaired), MCI and dementia stages. The best established ex-
amples include PET measurements of fibrillar Aβ deposition, PET
measurements of paired helical filament (PHF) tau deposition, MRI
measurements of hippocampal and whole brain atrophy, and fluor-
odeoxyglucose PET measurements of regional cerebral metabolic rate
for glucose (rCMRgl) decline in brain regions preferentially affected by
AD (Herholz and Ebmeier 2011; Reiman and Jagust 2012; Saint-Aubert
et al. 2017). In the most recent conceptualization (Jack et al. 2018),
biomarker evidence of amyloid-β (Aβ) pathology reflects “AD patho-
physiological change”, biomarker evidence of both amyloid-β and tau
pathology reflects “AD”, and individuals can also be characterized in
terms of the evidence of neurodegenerative disease changes that may
include rCMRgl declines and brain atrophy (i.e., “AT(N)” research cri-
teria for AD; Jack et al. 2018)).
AD and related disorders are associated with distinctive MRI and
FDG PET patterns of neurodegeneration. Some neurodegenerative dis-
eases appear to begin with or are characterized by asymmetric patterns
of neurodegeneration (e.g., Parkinson's Disease (PD) and Primary
Progressive Aphasia (PPA), (Claassen et al. 2016; Gorno-Tempini et al.
2004). While AD has been characterized by bilateral neurodegenerative
disease changes in medial temporal and heteromodal sensory associa-
tion areas, several neuroimaging studies have suggested a pronuncia-
tion of the left hemisphere with respect to amyloid deposition (Raji
et al. 2008) gray matter atrophy (Janke et al. 2001; Shi et al. 2009;
Thompson et al. 1998, 2001), cerebral perfusion and metabolism
(Friedland et al. 1985; Loewenstein et al. 1989; Volkow et al. 2002) in
persons with AD. Whereas many of these findings (particularly from
studies of brain metabolism) have been cross-sectional, we sought to
investigate the possibility that amyloid-β positive (Aβ+) persons might
demonstrate asymmetric left lateralized longitudinal patterns of neu-
rodegeneration, especially during the earlier clinical stages of AD. To
address this possibility we compared longitudinal patterns of rCMRgl
declines in Aβ+probable AD dementia, MCI and an amyloid-β nega-
tive (Aβ-) cognitively unimpaired control group from the AD Neuroi-
maging Initiative (ADNI).
2. Subjects and methods
2.1. Subjects
Participant data for this study were drawn from the ADNI dataset,
an ongoing longitudinal study (currently ADNI-3) devoted to the es-
tablishment of biological and neuroimaging biomarkers of MCI and
Alzheimer's disease. Detailed information on participant recruitment,
inclusion- and exclusion criteria are provided on the ADNI website
(www.adni-info.org/index.php). In order to maximise the sensitivity of
our analyses we only included amyloid-β negative (Aβ-) cognitively
unimpaired control subjects (CU) based on CSF measures
(threshold>192) or florbetapir PET (threshold<1.18) with cere-
bellum reference region, thereby optimally avoiding the inclusion of
subjects with preclinical and asymptomatic stages of AD. Similarly only
amyloid-β positive (Aβ+) MCI and AD patients were included, thus
avoiding misclassification of patients and maximising the probability of
AD pathology being the underlying cause of cognitive impairment. In
total, we selected a sample of n=167 subjects, based on availability of
longitudinal FDG PET scans and information on amyloid pathology,
resulting in a sample of 51 Aβ+subjects with AD dementia, 76
Aβ+subjects with MCI, and 40 Aβ- CU. In the following, we will refer
to MCI-AD and dementia-AD for MCI and dementia subjects with evi-
dence of AD pathology.
2.2. Clinical evaluation
For each subject, cognitive function was evaluated at each visit (for
details please see www.adni-info.org). Measures of cognitive function
included - next to others - the Auditory Verbal Learning Test [AVLT;
(Rey 1964)] Total and Long-Term Memory (LTM) scores, CDR sum of
boxes (CDR-SOB; (Morris 1993)), MMSE (Folstein et al. 1975), Category
Fluency (animals) (Rosen 1980) and the modified AD Assessment Scale-
Cognitive Subscale (i.e. ADAS-Cog 11/13; Mohs et al. 1997; Rosen et al.
1984). Delta values were calculated for each test and participant. In
addition subdomains and individual subitems of the ADAS-cog 13 were
analyzed with the goal to further evaluate baseline impairment and
subsequent decline of specific cognitive domains. Subitems of the
ADAS-cog 13 comprise the following cognitive subdomains: Memory
and new learning (i.e. Word Recall, Orientation, Word Recognition,
Delayed Word Recall, Recall Instructions), language (i.e. Commands,
Naming, Spoken Language, Word Finding, Comprehension), praxis (i.e.
Construction, Ideational Praxis) and processing speed (i.e. Number
Cancellation) with higher scores indicating worse performance. For the
item “Number Cancellation” data points were missing for N=5 sub-
jects (N=4 dementia-AD; N=1 CU). Since individual subitems of the
ADAS-cog 13 differ with respect to the maximum possible value, results
were illustrated as percentage of the maximum possible scores. Non-
imaging data were analyzed using ANOVA or Chi Square whenever
applicable. For post-hoc between group comparisons Duncan's multiple
range test was applied. Results are reported at alpha 0.05 uncorrected.
2.3. Imaging procedures
Longitudinal imaging data from different participating sites were
subjected to a standardized protocol (http://www.loni.ucla.edu/ADNI/
Data/ADNI_Data.shtml) of measured-attenuation correction and spe-
cific reconstruction algorithms in order to account for site specific
differences. These preprocessing steps were performed by the ADNI PET
Coordinating Center at the University of Michigan made available for
download at the LONI ADNI website. After download of PET images
additional pre-processing steps were performed using SPM5 (http://
www.fil.ion.ucl.ac.uk/spm), including deformation into a standard
space of the Talairach atlas and spatial smoothing with a 3-dimensional
Gaussian filter with 8mm full width at half maximum. Next, subtrac-
tion images of the FDG scans scaled by the global counts were calcu-
lated (i.e. baseline/global_at_baseline – followup/global_at_followup)
for characterization and comparisons of 24-month rCMRgl declines.
To test the hypothesis of lateralized longitudinal declines of rCMRgl
declines we used SPM8 (www.fil.ion.ucl.ac.uk) and the LI-toolbox
(Wilke and Lidzba 2007). First, SPM8 was used for voxel-based analyses
of rCMRgl declines by applying either two-sample t-test for group
comparisons or one sample t-tests for within group analyses to the
above mentioned subtraction images. In addition, post-hoc regression
analyses were performed to investigate associations of cognitive decline
[(i.e. ADAS-cog 13 and Category Fluency (animals)] with rCMRgl de-
clines in dementia-AD and MCI-AD subjects. Then, SPM derived T-maps
were analyzed with the LI-toolbox by calculating an overall weighted
bootstrapped lateralization index (LI) for the unthresholded maps. This
approach combines the commonly used lateralization eq. (LI= (left-
right)/(left+right)) with adaptive thresholding and automated boot-
strapping algorithms to minimize the impact of outliers. For our ana-
lyses we furthermore used an inclusive standard gray matter mask and
an additional exclusive mask (i.e. midline +/− 5mm) as provided by
the LI-toolbox, in order to reduce noise related artifacts. For the cal-
culated LI weighted means (LIwm), negative values indicate right
hemispheric lateralization and positive values indicate left hemispheric
lateralization. Based on the LIwm, lateralization was classified as either
absent (LIwm −0.25 to 0.25), weak (LIwm −0.25 to −0.50 and 0.25
to 0.50) or strong (LIwm<−0.50 and > 0.50) (e.g. De Winter et al.
2015). Importantly, this approach largely avoids the introduction of
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arbitrary thresholds and strongly reduces the impact of potential out-
liers.
The main goal of this study was to statistically quantify lateraliza-
tion of longitudinal rCMRgl declines, by using a global index that
provides information free of the type-1 error due to multiple compar-
isons, via the above mentioned analytical approach (i.e. the boot-
strapped lateralization indices for unthresholded maps). Since the in-
troduction of conservative thresholds may artificially create the
impression of lateralization, maps of rCMRgl declines were displayed
with an uncorrected voxelwise threshold of p < .005. Nevertheless,
additional information on whole-brain corrected results (FWE correc-
tion on the cluster-level; FWEc) is provided in the respective tables.
Detailed results of within group analyses and regression are ad-
ditionally provided as supplementary information. Results of the within
group one-sample t-tests of rCMRgl declines in MCI-AD and dementia-
AD patients are reported at p < .05 FWE voxel-level corrected (FWEv),
to avoid excessive clustering and provide better information on the
anatomical pattern of rCMRgl declines.
3. Results
3.1. Subject characteristics and cognitive performance
The subject groups' baseline characteristics are summarized in
Table 1, data of 24-month cognitive changes are provided as supple-
mentary data (Table S1). No significant differences were observed for
baseline age, gender distribution, education and time interval between
groups. As expected, in comparison with the CU group, the dementia-
AD and MCI-AD groups had a higher proportion of APOE4 carriers,
lower baseline cognitive performance, and greater 24-month cognitive
declines. For the sub-items of the ADAS-cog 13 at baseline (illustrated
in Fig. 1), most prominent deficits were observed for memory functions
[i.e. Delayed Word Recall, Word Recall, Word Recognition (all de-
mentia-AD>MCI-AD>CU) and Orientation (dementia-AD>MCI-
AD/CU)], Processing Speed [i.e. Number Cancellation (dementia-
AD>MCI-AD>CU)] and Praxis [i.e. Construction (dementia-AD>
MCI-AD>CU)], while only minor deficits were evident for language
functions [i.e. Word Finding and Naming (all dementia-AD/MCI-
AD>CU]. Similar results were seen when the respective subitems were
grouped as subdomains, again with most prominent deficits in the
memory subdomain (dementia-AD>MCI-AD>CU) and less profound
deficits in the praxis and language subdomain (dementia-AD>MCI-
AD>CU and dementia-AD/MCI-AD>CU). During the 2 year follow
up period cognitive decline again was most evident for memory func-
tions [i.e. Orientation (dementia-AD>MCI-AD>CU)], Word Recall,
Delayed Word Recall, Word Recognition (all 3 items dementia-AD/MCI-
AD>CU) and Recall Instructions (dementia-AD>MCI-AD/CU), fol-
lowed by Praxis (i.e. Ideational Praxis (dementia-AD>MCI-AD/CU)
and language functions [i.e. Word Finding, Naming, Commands,
Comprehension (all dementia-AD>MCI-AD/CU) and Spoken Lan-
guage (dementia-AD>CU)]. Analyses of the ADAS subdomains yielded
significant decline within the memory subdomain for both AD and MCI
subjects (dementia-AD>MCI-AD>CU) and within the language and
praxis subdomain for AD subjects only (both dementia-AD>MCI-AD/
CU).
For Category Fluency (animals) significant deficits were found at
baseline for dementia-AD and MCI-AD (dementia-AD>MCI-AD>CU)
with weakly significant 24-month decline (dementia-AD/MCI-
AD>CU).
3.2. 24-month rCMRgl declines
Compared to CU, MCI-AD patients showed rCMRgl declines pre-
dominantly located within the left lateral temporal cortex
Table 1
Baseline subject characteristics.
CU Aβ- MCI Aβ+ AD Aβ+ P value
(n=40) (n=76) (n=51)
Baseline age 76.1 ± 5.3 75.8 ± 6.8 75.2 ± 7.1 n.s.
*Gender (M/F) 20/20 51/25 31/20 n.s.
Education (years) 15.5 ± 3.2 16.3 ± 2.859 15.3 ± 3.2 n.s.
Timeinterval (years) 1.99 ± 0.26 1.95 ± 0.26 1.84 ± 0.44 n.s
*APOE E4 gene dose (NC/HT/HM) 32/8/0 32/30/14 8/28/15 4.98E-08
MMSE 28.6 ± 1.5 26.9 ± 1.9 23.4 ± 1.9 2.09E-29
CDR-SOB 0.1 ± 0.2 1.7 ± 1.0 4.3 ± 1.5 7.80E-43
AVLT-STM 8.3 ± 3.3 3.6 ± 3.1 1.4 ± 1.6 (50) 2.76E-22
AVLT-LTM 7.5 ± 3.8 2.1 ± 3.0 0.6 ± 1.5 4.62E-23
AVLT-Total 42.2 ± 9.2 29.4 ± 8.1 22.8 ± 6.8 (50) 1.05E-21
Category fluency (animals) 19.8 ± 4.8 15.5 ± 3.9 13.3 ± 4.2 1.03E-10
ADAS-cog 13 10.1 ± 4.5 (39) 20.0 ± 5.9 28.7 ± 7.6 (50) 6.89E-29
ADAS-cog 11 6.4 ± 3.0 12.1 ± 4.2 18.0 ± 6.0 6.94E-23
ADAS memory subdomain (0–45) 8.8 ± 4.3 17.0 ± 5.8 23.8 ± 5.9 7.47E-26
ADAS language subdomain (0–25) 0.3 ± 0.6 1.2 ± 1.2 1.4 ± 1.8 2.05E-04
ADAS praxis subdomain (0−10) 0.4 ± 0.6 0.7 ± 0.7 1.3 ± 0.8 1.29E-08
ADAS Q1 word recall (0–10) 3.0 ± 1.2 4.8 ± 1.2 6.0 ± 1.4 1.95E-21
ADAS Q2 commands (0–5) 0.1 ± 0.3 0.2 ± 0.5 0.3 ± 0.5 n.s.
ADAS Q3 construction (0–5) 0.3 ± 0.5 0.6 ± 0.6 1.0 ± 0.7 1.86E-07
ADAS Q4 delayed word recall (0–10) 3.1 ± 1.9 6.7 ± 2.3 8.5 ± 1.7 3.91E-25
ADAS Q5 naming (0–5) 0.1 ± 0.3 0.3 ± 0.5 0.3 ± 0.5 0.008
ADAS Q6 Ideational Praxis (0–5) 0.1 ± 0.3 0.1 ± 0.3 0.2 ± 0.4 <0.05
ADAS Q7 orientation (0–8) 0.2 ± 0.4 0.5 ± 0.8 2.5 ± 1.7 7.42E-21
ADAS Q8 word recognition (0−12) 2.6 ± 2.4 4.9 ± 3.0 6.7 ± 3.0 8.41E-10
ADAS Q9 recall instructions (0–5) 0.0 ± 0.2 0.1 ± 0.4 0.1 ± 0.4 n.s.
ADAS Q10 spoken language (0–5) 0.1 ± 0.2 0.1 ± 0.4 0.2 ± 0.6 n.s.
ADAS Q11 word finding (0–5) 0.1 ± 0.2 0.4 ± 0.6 0.5 ± 0.8 0.004
ADAS Q12 comprehension (0–5) 0.0 ± 0.2 0.1 ± 0.3 0.1 ± 0.5 n.s.
ADAS Q14 number cancellation (0–5) 0.5 ± 0.7(39) 1.1 ± 0.7 2.2 ± 1.5 (50) 1.14E-13
Data is presented as mean ± SD except for *.Group differences were assessed by ANOVA except for * (i.e. Chi-squared test); NC noncarriers; HT heterozygotes; HM
homozygotes; ADAS-cog Alzheimer's Disease Assessment Scale-cognitive subscale; MMSE Mini-Mental State Examination; CDR-SOB Clinical Dementia Rating Scale
Sum of Boxes; AVLT Auditory Verbal Learning Test; STM short term memory; LTM long term memory.
C.M. Weise et al. NeuroImage: Clinical 20 (2018) 286–296
288
(pFWEc < 0.05) (see Fig. 2 and Table 2). This pattern of rCMRgl de-
cline was found to be strongly left lateralized (LIwm 0.78).
Subjects with dementia-AD in comparison to CU exhibited bilateral
declines of rCMRgl (see Fig. 3 and Table 3), predominantly within the
temporal cortices (lateral>medial), the parietal lobes (i.e. bilateral
inferior parietal lobule), precuneus and the posterior cingulate (all
pFWEc < 0.05) with signs of weak right hemispheric lateralization
(LIwm −0.33).
Additional comparisons of dementia-AD patients with MCI-AD
patients yielded stronger and predominant right hemispheric rCMRgl
declines in dementia-AD patients (see Fig. 4 and Table 4), mostly within
the right temporal cortex (lateral>medial), the parietal lobe, pre-
cuneus, the posterior cingulate (one cluster, pFWEc < 0.05) and the
right frontal lobe (pFWEc < 0.05). This pattern of rCMRgl decline was
found to be strongly right lateralized (LIwm −0.79).
Within-group analyses yielded rCMRgl declines (pFWEv < 0.05) in
MCI-AD and dementia-AD, most prominently within the (posterior)
cingulate, the bilateral temporal and parietal lobes and the precuneus
Fig. 1. Mean baseline performance (top chart) and change over 24months (bottom chart) for the ADAS-cog 13 subitems for dementia-AD (AD), MCI-AD (MCI) and
cognitively unimpaired (CU) subjects. Results are illustrated as percentage of the maximum possible value, with higher values indicating worse performance.
Significant group differences are indicated by * (ANOVA: *p < .5; **p < .001; ***p < .0001; for detailed p-values see Table 1 and Table S1) with the corre-
sponding between group differences below in brackets (i.e. Duncan's multiple range test).
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with signs of weak left hemispheric lateralization for MCI-AD and weak
right hemispheric lateralization for dementia-AD (MCI-AD: LIwm 0.46;
dementia-AD: LIwm−0.44). rCMRgl declines were also observed in CU
subjects, yet less extended and in differing regions (i.e. mostly within
frontal and insular cortex and subcortical stuctures; all pFWEc < 0.05)
with signs of weak right hemispheric lateralization (CU: LIwm−0.48).
Fig. 2. T-score maps (p < .005 uncorrected) of greater 24-month rCMRgl declines in amyloid-β positive MCI-AD patients compared to amyloid-β negative cog-
nitively unimpaired controls (CU) with the corresponding histogram of bootstrapped lateralization indices (LIs).
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Additional information on within-group analyses is provided as sup-
plementary material (i.e. Table S1–3; Fig. S1–3).
3.3. Associations of 24-month rCMRgl declines with cognitive decline
Post-hoc regression analyses showed that cognitive worsening as
measured by the ADAS-cog 13 was associated (pFWEc < 0.05) with
rCMRgl declines within the left lateral temporal cortex in MCI-AD. This
pattern was found to be strongly left lateralized (LIwm 0.89). In de-
mentia-AD subjects, cognitive worsening was associated with bilateral
rCMRgl declines predominantly within the bilateral parietal lobule,
precuneus and the posterior cingulate (one large cluster at
pFWEc < 0.05) with signs of weak right hemispheric lateralization
(LIwm −0.28). Due to missing values in the dementia-AD group
(N=4) of Q14 (i.e. number cancellation) of the ADAS-cog 13 addi-
tional regression analyses were done with complete data of the ADAS-
cog 11 where the same pattern of associations was found (data not
shown), similarly with signs of weak right hemispheric lateralization
(LIwm −0.33).
Declines of verbal fluency [i.e. Category Fluency (animals)] did not
show any significant associations with rCMRgl declines in MCI-AD
subjects (all p > .6 FWEc). Uncorrected associations (p < .005) were
mainly located within the left basal ganglia next to a smaller cluster
within the left temporal cortex, overall with signs of strong left later-
alization (LIwm=0.7).
In dementia-AD subjects however, declines of verbal fluency
showed significant associations (p < .05 FWEc) with rCMRgl declines
within the left precuneus and parietal lobule, the left temporal and
frontal cortex. This pattern was found to be strongly left lateralized
(LIwm=0.7). Additional information on regression analyses is pro-
vided as supplementary material (i.e. Table S5–6; Fig. S4–6).
4. Discussion
To our knowledge, this is the first longitudinal FDG PET study to
investigate asymmetric patterns of rCMRgl decline in MCI and early
dementia stages of AD. In a well characterized sample of patients we
observed diverging patterns of asymmetric and/or lateralized rCMRgl
declines in Aβ+MCI-AD and dementia-AD patients compared to Aβ-
cognitively unimpaired controls (CU). While – in comparison to CU -
MCI-AD subjects yielded signs of strong left hemispheric lateralization,
early stages of dementia-AD were associated with right hemispheric
lateralization of rCMRgl, even though this effect was found to be
weaker as compared to MCI-AD patients. Consequently, rCMRgl de-
clines in dementia-AD patients compared to MCI-AD patients were
found to be strongly right lateralized. Similar directionalities of later-
alization were found for within-group analyses of rCMRgl declines in
MCI-AD and dementia-AD, however in MCI-AD patients left hemi-
spheric lateralization was weaker as when compared to CU, which in
turn showed rCMRgl declines of predominantly prefrontal brain regions
with signs of weak right hemispheric lateralization. Importantly, the
pattern of rCMRgl declines we observed in MCI-AD and dementia-AD
subjects was restricted to brain regions typically affected in AD, thus
closely resembling previous FDG-PET studies (e.g. Reiman and Jagust
2012). Although the estimation of lateralization with the LI-Toolbox
implies the use of a priori unthresholded imaging data, rCMRgl declines
within AD typical regions did reach statistical significance after cor-
rection for multiple comparisons, thus providing additional statistical
validation.
Additional analyses of cognitive data furthermore showed pre-
dominant decline of memory functions for ADAS-cog subitems and
subdomains. Importantly, no significant decline of the language sub-
domain was found for MCI-AD subjects. Post-hoc regression analyses of
the 24-month ADAS-cog changes furthermore yielded strong left
hemispheric lateralization of its associations with rCMRgl decline. On
the other hand, significant decline was found for tests of verbal fluency
[i.e. Category fluency (animals)] and results of regression analyses were
strongly left lateralized in both dementia-AD and MCI-AD.
FDG PET measurements of rCMRgl have been used in the detection,
tracking and differential diagnosis of AD and can be observed long
before clinical onset of AD (Reiman and Jagust 2012). Presumed pa-
thophysiological underpinnings of rCMRgl reductions in AD include
neuronal and glial derangements of mitochondrial and metabolic
functions and consecutive reductions in synaptic function and density
(Mosconi 2013). In contrast, earlier upstream pathophysiological
events such as amyloid deposition may have plateaued even before
clinical signs of AD are noticeable (Jack et al. 2010). Consequently,
FDG PET may be more reflective of the clinical course of AD. Im-
portantly, reductions in rCMRgl are sought to precede brain atrophy
and alterations in glucose metabolism cannot be solely explained by
brain atrophy and increases in CSF spaces (Ibáñez et al. 1998; Jack et al.
2010).
Within the past decades the question whether AD pathology de-
velops in an asymmetric or lateralized fashion has been investigated by
numerous studies, yet with conflicting results. While post-mortem stu-
dies yielded a high variability of AD pathology for the left and right
hemisphere, no clear signs of asymmetry or lateralization were ob-
served (Janota and Mountjoy 1988; Wilcock and Esiri 1987). In con-
trast, PET measurements of amyloid deposition in MCI and AD patients
were found to be weakly left lateralized for some brain regions in MCI
and right lateralized in AD, somewhat similar to the pattern of rCMRgl
declines we observed in our within-group analyses (Raji et al. 2008). It
has to be noted though that these observations were made in a small
sample and still require additional confirmation by further studies.
Earlier studies of brain metabolism in AD and subjects at high risk
for AD showed asymmetric reductions in cerebral glucose uptake, in
parts with predominant left hemispheric metabolic deficits (Friedland
et al. 1985; Loewenstein et al. 1989; Siegel et al. 1996; Small et al.
1995) while asymmetric glucose metabolism was found to correlate
with cognitive dysfunction of lateralized domains such as language (i.e.
left hemisphere) or visuospatial processing (i.e. right hemisphere)
(Haxby et al. 1985). Similar observations had been made by Keilp et al.
with differing correlations of left and right hemispheric perfusion def-
icits with specific cognitive domains in AD (Keilp et al. 1996). In ad-
dition, more recent studies found marked left hemispheric decrements
in FDG uptake in AD patients (Volkow et al. 2002). Consideration of
hemispheric differences in AD has also been given in brain structural
studies. Observations of accentuated left ventricular enlargement in
early AD were – in parts – confirmed by more sophisticated analyses of
Table 2
24-month rCMRgl declines in amyloid-β positive MCI-AD patients compared to
amyloid-β negative cognitively unimpaired controls.
Region k p(unc) MNI (mm)
x y z
L Inferior Temporal Gyrus 1362 7.95E-06† −64 −32 −18
L Middle Temporal Gyrus 2.11E-05 −60 −46 −14
L Inferior Temporal Gyrus 0.0002 −58 −64 −8
L Middle Temporal Gyrus 2200 6.47E-05⁎ −52 −68 22
L Superior Parietal Lobule 0.0001 −38 −64 50
L Precuneus 0.0003 −34 −78 42
L Parahippocampal Gyrus 161 0.0004 −38 −22 −30
L Precuneus 159 0.0014 −6 −50 34
L Precuneus 0.0025 −4 −64 34
L Cingulate Gyrus 0.0040 0 −32 34
Results are listed at p < .005 uncorrected and a cluster size threshold of 100
continuous voxels. Bold data indicate primary peaks within a cluster, non-bold
data indicate secondary peaks within the cluster. MNI: Montreal Neurological
Institute; p(unc): uncorrected p-value; k: cluster size.
⁎ p < .05 FWE corrected on the cluster-level.
† p < .1 FWE corrected on the cluster-level.
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Fig. 3. T-score maps (p < .005 uncorrected) of greater 24-month rCMRgl declines in amyloid-β positive dementia-AD patients compared to amyloid-β negative
cognitively unimpaired controls (CU) with the corresponding histogram of bootstrapped lateralization indices (LIs).
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brain morphometry with detailed characterization of the spatial dy-
namics of brain atrophy in AD. Here, affirmative to studies of brain
metabolism, asymmetric patterns of gray matter loss in AD with a left
hemispheric pronunciation were demonstrated (Janke et al. 2001;
Thompson et al. 1998, 2001). Specific focus has also been given to the
hippocampus with meta-analyses showing a consistent left-less-than-
right hippocampal volume in MCI and AD patients but also control
subjects. While effect sizes were the strongest in MCI subjects, these
results indicate dynamic changes of physiological asymmetry patterns
during the course of the disease (Shi et al. 2009). On the other hand,
Derflinger et al. argued that findings of left lateralized AD pathology are
mainly attributable to a selection bias introduced by largely language
based cognitive assessments (Derflinger et al. 2011). In our sample post-
hoc regression analyses showed that 24-month cognitive decline
(ADAS-cog) was significantly associated with rCMRgl decline in both
dementia-AD and MCI-AD subjects with patterns closely resembling the
results from our group comparisons. Whereas for dementia-AD subjects
bilateral decline with at most weak right hemispheric lateralization was
seen, evidence of strong left hemispheric lateralization was found for
associations of cognitive decline with rCMRgl declines in MCI-AD pa-
tients. For both MCI and AD subjects cognitive deficits at baseline and
longitudinal decline of the ADAS-cog subitems were most pronounced
in tests representative of memory performance, processing speed and
praxis while language functions were only modestly affected at baseline
and decline was only evident in dementia-AD but not MCI-AD patients,
overall consistent with ADNI's focus on memory impairment (Petersen
et al. 2010). Similar results were obtained when subitems were grouped
to subdomains (i.e. memory, language, praxis), again without sig-
nificant decline of the language subdomain in MCI-AD subjects. While
ADAS-cog provides a general measure of cognitive function we ad-
ditionally analyzed Category Fluency (animals), a more language fo-
cused cognitive assessment of semantic fluency, with known left la-
teralization in healthy subjects as well as AD patients (Gutierrez-Sigut
et al. 2015; Meinzer et al. 2009; Yeung et al. 2016; Zahn et al. 2004).
Here, we did find weak but significant 24-month decline in both de-
mentia-AD and MCI-AD with regression analyses yielding strong left
hemispheric lateralization for the respective associations with rCMRgl
decline, confirmatory to previous reports (Zahn et al. 2004). Never-
theless, in MCI-AD subjects, these associations did not reach statistical
significance (all p > .6 FWEc) with the largest cluster located within
subcortical structures (i.e. caudate nucleus).
Overall, these findings suggest that left hemispheric rCMRgl de-
clines in our sample of MCI-AD subjects are not the primary result of a
selection bias due to earlier detection of language impairment and/or
predominant decline of language functions.
Thus far, no clear-cut explanation or potential mechanism has been
provided for why left hemispheric brain regions could be more sus-
ceptible towards AD related neurodegeneration. Strong evidence in-
dicates that brain regions associated with the default mode network
(DMN) – a network of distinct brain regions characterized by increased
activity under resting conditions – are particularly affected by AD pa-
thology (Greicius et al. 2003).
This in turn lead to the hypothesis that acquired lifetime cerebral
metabolism of DMN regions facilitates AD related pathophysiological
mechanisms, thus providing a potential explanation for the selective
neuronal vulnerability that is seen in AD (Buckner et al. 2005). Indeed,
earliest Aβ accumulation appears to manifest mainly within medial
brain regions that form part of the DMN, while later stages of Aβ ac-
cumulation include large parts of the neocortex (Palmqvist et al. 2017).
Brain regions of the DMN – next to others – include the PCC, precuneus
as well as lateral and medial temporal lobe structures. Intriguingly, two
studies focusing on the lateralization of DMN activity in healthy sub-
jects showed left hemispheric lateralization, potentially supporting our
and previous observations of left lateralized pathology in MCI
(Agcaoglu et al. 2015; Swanson et al. 2011). However, AD seems to be
characterized by diverging trajectories of regional Aβ pathology and
brain metabolic declines (Perani 2014) and although DMN alterations
are well established in AD (Pievani et al. 2017), it still remains to be
clarified whether these changes develop in an asymmetric or even la-
teralized manner. Hence further research is required to shed light on
the intricate interplay of pathophysiological processes that may lead to
a potentially lateralized selective neuronal vulnerability in AD.
Potential support for a higher left hemispheric susceptibility to-
wards AD related neurodegeneration may also be provided by the lo-
gopenic variant of primary progressive aphasia (lpPPA), a focal variant
of AD with typical AD pathology and distinct patterns of left lateralized
temporoparietal atrophy and hypometabolism (Galton et al. 2000;
Gorno-Tempini et al. 2004; Henry and Gorno-Tempini 2010; Madhavan
et al. 2013; Rohrer et al. 2012). Of note though, other focal variants
such as the posterior cortical atrophy exist, that do not present with
obvious lateralized pathological hallmarks (Ossenkoppele et al. 2015).
Somewhat contrasting, we found weak respectively strong right
hemispheric lateralization in AD patients when compared to healthy
controls and MCI-AD patients, indicating that metabolic differences
between hemispheres develop in a dynamic fashion and seem to di-
minish with further progression of the disease. This discrepancy needs
to be interpreted under consideration of current theories on mechan-
isms related to disease progression. Both animal and human research
support the concept of AD pathology spreading via neuronal transport
and transsynaptic diffusion within interconnected brain regions (such
as the DMN) which – in theory- would allow for interhemispheric
spreading of to begin with more lateralized pathological changes such
as Aβ deposition and TAU formation (Jucker and Walker 2013; Walker
et al. 2013).
Several limitations of our study need to be acknowledged. First, this
is an exploratory study of preexisting data. However, this limitation is
compensated for by the detailed characterization of patients and con-
trols of the ADNI cohort, its comparably large sample sizes and the
longitudinal data. We also acknowledge the fact that evidence for
strong left hemispheric lateralization was only seen in MCI-AD patients
when compared to CU, while within group analyses showed same-di-
rectional but weaker effects. Nevertheless, comparisons against control
subjects are mandatory as over time rCMRgl declines in healthy sub-
jects as well and hence needs to be controlled for in order to distinguish
AD related pathology from effects related to normal aging (Berti et al.
2014). In this context we also want to stress that by the inclusion of
Table 3
24-month rCMRgl declines in amyloid-β positive dementia-AD patients com-
pared to amyloid-β negative cognitively unimpaired controls.
Region k p(unc) MNI (mm)
x y z
R Inferior Parietal Lobule 11,225 3.51E-07⁎ 58 −50 52
R Inferior Parietal Lobule 4.39E-07 52 −56 52
R Inferior Temporal Gyrus 8.30E-07 58 −48 −14
L Middle Temporal Gyrus 6845 9.79E-07⁎ −62 −46 −14
L Inferior Parietal Lobule 1.74E-06 −60 −44 48
L Middle Temporal Gyrus 6.41E-06 −52 −70 22
L Precuneus 4067 5.15E-06⁎ 0 −68 44
L Cingulate Gyrus 5.64E-06 −2 −34 30
L Precuneus 0.0002 −6 −46 34
L Caudate 125 0.0003 −10 10 8
L Middle Frontal Gyrus 347 0.0009 −26 28 60
L Superior Frontal Gyrus 0.0014 −16 10 76
L Middle Frontal Gyrus 0.0004 −30 14 64
R Middle Frontal Gyrus 460 0.0006 38 12 64
R Middle Frontal Gyrus 0.0007 44 4 66
Results are listed at p < .005 uncorrected and a cluster size threshold of 100
continuous voxels. Bold data indicate primary peaks within a cluster, non-bold
data indicate secondary peaks within the cluster. MNI: Montreal Neurological
Institute; p(unc): uncorrected p-value; k: cluster size.
⁎ p < .05 FWE corrected on the cluster-level.
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exclusively MCI and AD patients with, and control subjects without
evidence of Aβ pathology high specificity of our findings with respect to
AD as probable cause is ensured. However, as Aβ pathology was
determined based on availability of CSF measures or AV-45 PET ima-
ging data, additional analyses to investigate the relationship between
regional amyloid burden and rCMRgl declines in the context of
Fig. 4. T-score maps (p < .005 uncorrected) of greater 24-month rCMRgl declines in amyloid-β positive dementia-AD patients compared to amyloid-β positive MCI-
AD patients with the corresponding histogram of bootstrapped lateralization indices (LIs).
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hemispheric lateralization were not feasible in this sample, a question
that should be addressed by future studies.
5. Conclusion
We found left lateralized 24-month rCMRgl declines in Aβ positive
persons with MCI, which are not apparent in the dementia stages of AD.
It remains to be clarified whether this decline reflects preferential
vulnerability to the early stages of AD or neurodegenerative patterns
that account for the clinical (e.g. verbal memory) features of MCI.
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